---
figid: PMC9600404__cancers-14-05074-g003
pmcid: PMC9600404
image_filename: cancers-14-05074-g003.jpg
figure_link: /pmc/articles/PMC9600404/figure/cancers-14-05074-f003/
number: Figure 3
figure_title: ''
caption: 'Molecular pathways in iCCA. Inhibitors have been developed for well-known
  signaling pathways including the Raf/MEK/ERK, PI3K-AKT, and JAK/STAT pathway. AKT:
  protein kinase B; FGFR: fibroblast growth factor; HER2: epidermal growth factor
  receptor 2; JAK: janus kinase; mTOR: mammalian target of rapamycin; PI3K: phosphoinositide
  3-kinase. NTRK: neurotrophic receptor tyrosine kinase.'
article_title: 'Newest Therapies for Cholangiocarcinoma: An Updated Overview of Approved
  Treatments with Transplant Oncology Vision.'
citation: Yuqi Zhang, et al. Cancers (Basel). 2022 Oct;14(20):5074.
year: '2022'

doi: 10.3390/cancers14205074
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI

keywords:
- cholangiocarcinoma
- targeted therapy
- transplant oncology
- immunotherapy

---
